Here, read about a case of atypical Wernicke’s encephalopathy in a woman with avoidant/restrictive food intake disorder presenting with bilateral ophthalmoplegia and normal serum thiamine levels.
Autoimmune encephalitis (AE) is a highly treatable neurologic condition that can cause psychosis. This study estimated the cost-effectiveness of routine screening for AE compared with clinically targeted screening in first-episode psychosis patients.
As both delirium and short-term memory impairment can be presenting symptoms in both Wernicke-Korsakoff syndrome and antibody-mediated limbic encephalitis, the potential of misdiagnosis and delayed treatment can occur. Read this interesting case report to find out more.
The authors of this letter to the editor question the diagnosis of a patient in a case report previously published in The Primary Care Companion for CNS Disorders.
Thymomas are commonly associated with myasthenia gravis. However, this case highlights that thymomas may also be related to limbic encephalitis. Read on to find out more.
Although psychiatric manifestations are one of the most common presentations of pediatric N-methyl-d-aspartate receptor encephalitis, there is a lack of studies that characterize psychiatric aspects of this disorder. This study, which included 21 children, was designed to address this gap. Read on to find out more.
Diagnosis of autoimmune encephalitis is often difficult and frequently delayed given the time taken to rule out more common psychiatric and neurologic conditions. Here, read about a complex case of autoimmune encephalitis with comorbid sinus venous thrombosis.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT